BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Accuray Inc. (ARAY) CEO Euan Thomson Quits


10/18/2012 8:16:19 AM

San Francisco Business Times by Steven E.F. Brown, Web Editor

Euan Thomson quit as president and CEO of Accuray Inc. on Oct. 11.

The Sunnyvale company (NASDAQ: ARAY) replaced him the next day with Joshua Levine, 54, who was also given a seat on the board of directors to fill the empty spot left by Thomson.

According to the details of Accuray's report to the Securities and Exchange Commission on Wednesday, Levine "attended to personal matters" for the last year before he was hired. From June 2011 to October 2011 he was president and CEO of Immucor Corp. In the past, he worked 14 years at Mentor Corp., which makes medical devices.

Levine's salary will be $625,000, and he'll get 90 days of "reasonable business expenses and temporary housing expenses" not to exceed $6,000 a month, reimbursed by the company, according to his employment agreement.

His bonus will be as much as 120 percent of his salary, or $750,000.

Accuray makes cancer treatment technology, including radio surgery and radiation therapy devices, some of which are sold under the "CyberKnife" brand.

In the year ended June, Accuray lost $72 million on sales of $409.2 million. At that time, the company had accumulated a deficit of $216.4 million.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES